M.D., Johns Hopkins University School of Medicine, 1968
firstname.lastname@example.org | (516) 367-5420
I’m studying how to harness the power of the immune system to fight cancer. Our underlying premise is that the microenvironment within a tumor suppresses the immune system. We have found a way to eliminate this suppression in the mouse model of pancreatic cancer, which has led to development of a drug for human pancreatic cancer that will enter phase 1 clinical trials in 2015.
The Fearon laboratory studies the interaction between cancer and the immune system. Our underlying premise is that the tumor microenvironment is immune suppressive because cancer cells elicit responses characteristic of wound healing and tissue regeneration. This approach has led to the finding that activated fibroblasts in the tumor stroma mediate immune suppression in several mouse models of cancer, including the autochthonous model of pancreatic ductal adenocarcinoma of the Tuveson lab. Our understanding of the basis of immune suppression is evolving, but we know that it involves the production of the chemokine, CXCL12, by the fibroblastic stromal cells, binding of this CXCL12 by pancreatic cancer cells, and exclusion of T cells from the vicinity of the cancer cells. T cell exclusion, which also occurs in several types of human adenocarcinomas, causes antagonists of T cell checkpoints to be ineffective, despite the presence of cancer-specific CD8+ T cells. This immune suppression is interrupted by administering AMD3100, an inhibitor of CXCR4, the receptor for CXCL12, which leads to the rapid accumulation of T cells amongst cancer cells, thereby uncovering the efficacy of anti-PD-L1 and eliminating cancer cells. Since human pancreatic cancer has certain immunological characteristics of the mouse model, a phase 1 clinical trial of AMD3100 in patients with pancreatic cancer will be initiated in 2015. Some of our next steps are to determine the biological process that causes cancer cells to express non-mutated, shared antigens, and the means by which dormant metastases escape immune elimination.
Big bold dreamers
December 10, 2018
Dreamers drive discoveries. CSHL honors its many scientists making big impacts in their respective fields.
How pancreatic cancer spreads after surgery
May 17, 2018
Researchers have solved a mystery about how pancreatic cancer spreads
How deadly cancer spreads after surgery
May 17, 2018
Scientists have solved an important mystery about how pancreatic cancer spreads to the liver even after a successful surgery.
The immune system, unleashed
May 15, 2018
Cancer immunotherapy has a long and storied history, one that begins with a young woman suffering from a pain in her hand
Bringing immune cells back into the cancer fight
May 4, 2018
Doug Fearon used a mouse model to discover how pancreatic cancer hides from the immune system.
One experiment: When cancer is hiding in plain sight
March 1, 2018
Douglas Fearon's team is figuring out how to get immune cells to recognize—and kill—pancreatic cancer cells
Turning off the immune system is hard. Turning it on against cancer is easier.
January 10, 2018
How Professor Doug Fearon’s experiences with autoimmune disease patients contributed to the discovery of a new potential immunotherapy for cancer.
The latest research in immunotherapy and cancer
July 28, 2017
Drs Douglas Fearon (CSHL) and Robert Maki (Northwell Health) talk about the latest science and how immunotherapy is already affecting patient lives.
Pancreas and colon tumors reprogram the liver, causing wasting and short-circuiting body’s immune response
November 8, 2016
Research reveals a mechanism that causes wasting in cancer and tests a way to reverse it.
New senior faculty join CSHL
November 10, 2014
Interviews with new faculty Adam Siepel and Douglas Fearon.